John McDermott

Chairman & Chief Executive Officer
Endologix Inc.

John McDermott is chairman and chief executive officer of Endologix, a medical device company that manufactures minimally invasive treatments for aortic disorders with a focus on endovascular stent grafts for abdominal aortic aneurysms (AAA), with revenues exceeding $150 million. McDermott joined in May 2008 and has more than 20 years of executive management, sales, marketing and finance experience in the vascular device industry.

From 2002 to 2007, McDermott served as president of Bard Peripheral Vascular, a division of C.R. Bard, Inc. He previously served as president of global sales for C.R. Bard's vascular surgery and endovascular businesses with responsibilities for managing a worldwide direct sales force with more than 200 representatives.

McDermott is an active leader within the vascular community and is currently on the board of directors of the International Society of Endovascular Specialists.